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OBJECTIVE: To assess the effect of hyperthermic intraperitoneal chemotherapy (HIPEC) to eradicate
intraperitoneal free cancer cells and to explore the feasibility of cytological cure for peritoneal carcinomatosis
(PC). METHODS: The peritoneal lavage fluid (or ascites) from 50 PC patients was collected before and after
intraoperative HIPEC, respectively, for conventional cytology test, and conventional and real-time quantitative
reverse transcript polymerase chain reaction detecting carcinoembryonic antigen (CEA) mRNA and cytokeratin-20
(CK20) mRNA. The blood samples 3 days before and 7 days after intraoperative HIPEC were also collected for
detecting the serum tumor markers, including CEA, carbohydrate antigen (CA) 125, and CA19-9. RESULTS: The
positive rate of conventional cytology test before HIPEC versus after HIPEC was100.0% versus 22.0% (P = .000).
The positive rates of CEA mRNA and CK20 mRNA before HIPEC versus after HIPEC were 100.0% versus 86.0%
(P = .012) and 100.0% versus 96.0% (P = .495), respectively. Moreover, after HIPEC, 18 (36.0%) patients had a
decline in CEA mRNA (P = .000), and 17 (34.0%) patients had a decline in CK20 mRNA (P = .000). The positive
rates of serum CEA, CA125, and CA199 before HIPEC versus after HIPEC were 52.0% versus 28.0% (P = .014),
52.0% versus 44.0% (P = .423), and 40.0% versus 28.0% (P = .205), respectively. CONCLUSION: HIPEC could
effectively eradicate intraperitoneal free cancer cells and partially achieve cytological cure for PC.
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Peritoneal carcinomatosis (PC) is one of the most frequent types of
cancer recurrence after curative resection in gastrointestinal and
gynecological cancers [1]. PC develops from micrometastasis, which
originated from intraperitoneal free cancer cells (IFCCs). These cells first
attach to the peritoneal surface and then migrate into the subperitoneal
tissue, resulting in the formation of the peritoneal micrometastasis,
which is thus thought to be the origin of recurrence [2].
Generally, PC patients have a very poor prognosis with less than 6
months of median survival [3]. The most widely accepted therapies
for such patients are systemic chemotherapy, best support care, and
palliative treatment, without any hope of cure. Over the past three
decades, PC is no longer universally considered as terminal cancer
metastasis but as regional tumor progression [4]. Moreover, aggressive
cytoreductive surgery (CRS) plus hyperthermic intraperitoneal
chemotherapy (HIPEC) has been developed as an integrated
treatment package and has brought significant survival benefit inselected patients [5]. Major technical advantages of this treatment
approach are to maximally reduce the visible tumor burden by CRS
and to eradicate residual tumor nodules, micrometastases, and free
tumor cells by HIPEC.
Table 1. Primers Sequences in This Study
ID Primer Sequences Product Size
CEA A: 5′-TCTGGAACTTCTCCTGGTCTCTCAGCTGG-3′ 131 bp
B: 5′-TGTAGCTGTTGCAAATGCTTTAAGGAAGAAGC-3′
C: 5′-GGGCCACTGTCGGCATCATGATTGG-3′
CK20 Forward: 5′-CAGACACACGGTGAACTATGG-3′ 370 bp
Reverse: 5′-GATCAGCTTCCACTGTTAGACG-3′
GAPDH Forward: 5′-CAAGGTCATCCATGACAACTTTG-3′ 496 bp
Reverse: 5′-GTCCACCACCCTGTTGCTGTAG-3′
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studies on the feasibility, efficacy, and safety of this multidisciplinary
treatment approach in animal models [6] and in clinical settings [3]
and established a designated CRS + HIPEC center. The survival
benefits of this treatment package have been demonstrated in patients
with PC that originated from gastric cancer [7,8] and colorectal
cancer [9,10]. In this study, we collected the peritoneal lavage fluid
(or ascites) and blood samples before and after intraoperative HIPEC
of 50 PC patients and analyzed the changes of IFCCs, carcinoem-
bryonic antigen (CEA) mRNA, cytokeratin-20 (CK20) mRNA, and
serum tumor makers to assess the effect of HIPEC to eradicate IFCCs
and the explore feasibility of cytological cure for PC.
Materials and Methods
Patient Selection
This study included 50 consecutive Chinese patients with PC that
originated from gastric cancer, colorectal cancer, epithelial ovarian
cancer, or appendix mucinous adenocarcinoma, all treated by CRS +
HIPEC procedures fromOctober 2014 to August 2015 at our hospital.
The inclusion criteria were: 1) age 20 to 75 years old; 2) Karnofsky
performance status N50; 3) life expectancy N8 weeks; 4) normal
peripheral blood white blood cells count ≥3500/mm3 and platelet
count ≥80,000/mm3; 5) acceptable liver function, with bilirubin ≤ 2×
the upper limit of normal (ULN) and aspartic aminotransferase and
alanine aminotransferase ≤ 2× ULN; 6) acceptable renal function, with
serum creatinine ≤1.5 mg/dl; and 7) cardiovascular pulmonary and
othermajor organ functions can standmajor operation.Major exclusion
criteria were: 1) age b20 years or N75 years; 2) any lungmetastasis, liver
metastasis, or prominent retroperitoneal lymph node metastasis during
preoperative assessment; 3) serum bilirubin level N2× ULN; 4) liver
enzymes N2× ULN; and 5) serum creatinine level N1.5 mg/dl.
Informed consents were obtained from all patients, and the study was
approved by the institutional review board and the ethics committee.
CRS Plus HIPEC Procedure
All CRS + HIPEC procedures were conducted by a designated
team focusing on PC treatment. In brief, the abdominal exploration
was performed through a midline xiphoid-pubic incision after general
anesthesia, and peritoneal cancer index (PCI) was evaluated according
to the Sugarbaker criteria [11]. Then, maximal CRS was performed.
The extent of CRS was determined by the Sugarbaker criteria [12] on
the completeness of cytoreduction (CC). A score of CC-0 indicates
no residual peritoneal disease after CRS; CC-1, less than 2.5 mm of
residual disease; CC-2, residual tumor between 2.5 mm and 2.5 cm;
and CC-3, more than 2.5 cm of residual tumor or the presence of a
sheet of unresectable tumor nodules.
The HIPEC was implemented by the open Colliseum technique,
and with paclitaxel 120 mg and lobaplatin 100 mg each dissolved in 6
l of heated saline with temperature of 43.0°C ± 0.5°C. The total
HIPEC time was 60 minutes, with a flow rate of 400 ml/min, after
which gastrointestinal anastomoses or stoma was made. After
operation, the patient was delivered to the intensive care unit for
recovery. When the condition stabilized, the patients were transferred
to the surgical oncology ward.
Peritoneal Lavage
Ascites fluid (50 ml) was collected from the deep abdominal cavity
(spleen fossa, Douglas pouch, paracolic sulci) at laparotomy. In
patients with scanty ascites, 50 ml of saline was introduced into theabdominal cavity at the beginning of the operation and aspirated after
general stirring. After HIPEC, 50 ml of peritoneal washing fluid was
aspirated. These washes were equally divided into three parts, and all
were centrifuged at 2000 rpm at 4°C for 10 minutes to collect intact
cells. One part of each peritoneal wash was examined cytopatholo-
gically after conventional Wright’s staining, and the other two parts
were stored at −80°C until use for reverse transcriptase-polymerase
chain reaction (RT-PCR).
Conventional Cytology Examination
The cell sediments were smeared onto a glass slide, stained by
Wright’s method, observed with Olympus BX51 microscopy, and
photographed by Olympus DP72 image collecting system. Experi-
enced cytopathologists performed cytological evaluation. The smears
were classified according to their cytological features, as follows: 1)
IFCC positive: Cells were arranged mainly in loose clusters with the
occasional presence of floating cells. Nuclear cytoplastic rate was
disturbed. Nuclei were usually eccentric, with a thick nuclear
membrane, large prominent nucleoli, and coarsely granular chroma-
tin. 2) IFCC negative: Normal cells are present, or cells showonly
milder changes of chromatin. 3) Cancer cell cytolysis: Cancer cells lost
cell membrane integrity and with karyolysis, pyknosis, or karyor-
rhexis. Cell debris are dispersing into extracellular space.
Total RNA Extraction and cDNA Synthesis
Frozen samples were thawed, and total RNA was extracted using
RNAsimple Total RNA kit (TIANGEN, Beijing, China) by a
guanidinium-isothiocyanate-phenol-chloroform–based method.
cDNA was generated with a first-strand cDNA synthesis Kit
(Thermo, Waltham, MA) using the protocol recommended by the
manufacturer. Extracted total RNA (up to 5 μg) was preincubated
with 50 ng of oligo (dT)18 primer in 9 μl of solution for 5 minutes at
65°C. After chilling on ice, 4 μl of five-fold synthesis buffer (250 mM
Tris-HCl, pH 8.3, 250 mM KCl, 20 mM MgCl2, 50 mM
dithiothreitol), 1 μl of 20 U/μl RiboLock RNase inhibitor, 2 μl of
2.5 mM each dNTP, and 1 μl of 200 U/μl RevertAid- M-MuLV
reverse transcriptase were added. The reaction mixture was then
incubated for 60 minutes at 42°C and then heated at 70°C for
5 minutes, and the resultant first-strand cDNA was immediately used
for PCR solution.
Conventional RT-PCR
The integrity of isolated RNA was proven by RT-PCR analysis of a
housekeeping gene, glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Only samples with positive bands for GAPDH under-
went the steps described below. Each series of RT-PCRs included
RNA-negative samples as negative control, and mRNA from MGC
803 cells, which are well known to express high amounts of CEA and
CK20, as a positive control. CEA-specific oligonucleotide primers for
Table 2. Major Clinicopathologic Characteristics of the 50 Patients in This Study





Median age (range) 58 (26-75)
b60 32
≥60 18
Median KPS score (range) 80 (70-90)
PC origin
Gastric cancer 11 (22.0)
Colorectal cancer 18 (36.0)
Epithelial ovarian cancer 9 (18.0)
Appendix mucinous adenocarcinoma 8 (16.0)
Peritoneum malignant mesothelioma 4 (8.0)
Ascites (ml)
Scanty ascites 12 (24.0)
b1000 ml 18 (36.0)
≥1000 ml 20 (40.0)
PCI






KPS, Karnofsky performance scale.
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GAPDH-specific primers were listed in Table 1. All the primers were
synthesized by Sangon Biotech (Shanghai, China). All the PCRs were
carried out in a 25-μl reaction mixture containing 12.5 μl of 2× Taq
MasterMix (CWBIO, Beijing, China), 0.4 μM primers, and 1 μl of
template cDNA. For CEA, 20 rounds of amplification were
performed with primers A and B in a thermal cycler (Applied
Biosystems, Grand Island, NY) at 94°C for 1 minute and 72°C for 2
minutes and 30 seconds, with a final extension step at 72°C for 10
minutes. One-microliter aliquots of reaction product were then
transferred into second tubes containing the identical reaction
mixture except for the primers C and B. Twenty more cycles were
run at 94°C for 1 minute and 72°C for 2 minutes and 30 seconds with
a final extension step for 10 minutes. For CK20, denaturation was
performed for 1 cycle at 94°C for 3 minutes and 38 cycles of 94°C for
1 minute, 60°C for 45 seconds, and 72°C for 45 seconds. For
GAPDH, denaturation was performed for 1 cycle at 94°C for 30
seconds and 35 cycles of 94°C for 30 minutes, 58°C for 30 seconds,
and 72°C for 45 seconds. Six-microliter quantities of the final
products were then run on 1.5 % agarose gels, followed by ethidium
bromide staining. The images were collected using a gel imaging
system (Bio-Rad, Hercules, CA). Samples with visible 131–base pair
(bp), 370-bp, and 496-bp bands were designated as CEA, CK20, and
GAPDH positive, respectively. All necessary precautions against
contamination of PCRs were rigorously applied. The nucleotide
sequences of the PCR products were confirmed by the dideoxy chain
termination sequencing method.
Real-Time RT-PCR
The one-step real-time quantitative PCRs were carried out in a
20-μl reaction mixture containing 10 μl 2 × SYBR Premix EX Taq
II (Takara, Tokyo, Japan), 0.4 μM primers, and 1 μl of template
cDNA. The primers were the same with the conventional RT-PCR
(Table 1) except for CEA amplification, in which only primer B
and primer C were used. Also, each series of real-time RT-PCRs
included the same positive and negative control as mentioned
above. All real-time RT-PCRs were performed at CFX96 real-time
PCR detection system (Bio-Rad, Hercules, CA) following the same
temperature profile with conventional RT-PCR. Fluorescence was
measured at the end of the annealing period of each cycle to
monitor amplification.
Serum Tumor Makers
Three milliliters of blood were obtained from each patient 3 days
before surgery and 7 days after surgery, respectively. The serum was
separated immediately, and then CEA, carbohydrate antigen (CA)
125, and CA19-9 were detected using a full-automatic electrochem-
istry luminescence immunity analyzer (Roche, Basel, Switzerland).
The definitions of CEA, CA125, and CA19-9 positive were ≥5 ng/ml,
≥35 U/ml, and ≥37 U/ml, respectively.Statistical Analysis
All statistical calculations were done with SPSS 20.0 statistical
software (SPSS Inc., Chicago, IL). The figures show the mean ±
standard deviation. The chi-square test or Fisher exact probability test
and Student’s t test for paired sample were used to analyze the
quantitative data. The real-time quantitative RT-PCR relative
quantity analysis used 2−ΔΔct method with GAPDH as control
group. The level of statistically significance was set at P b .05.Results
Major Clinical-Pathological Characteristics
Fifty patients with PC that originated from gastric cancer,
colorectal cancer, epithelial ovarian cancer, appendix mucinous
adenocarcinoma, and peritoneum malignant mesothelioma, all
pathology confirmed, were included in this study. The details of
these 50 patients were listed in Table 2.
Result of Conventional Cytology
The IFCC-positive rate before HIPEC versus after HIPEC was
100.0% versus 22.0% (P = .000), respectively. Moreover, 14 patients
became IFCC negative, and 25 patients were found to have cytolysis
after HIPEC (Figure 1).
Result of Conventional RT-PCR
GAPDH shows a clear band at 496 bp for each sample. All the
positive controls for CEA, CK20, and GAPDH show clear bands at
corresponding sites, and all negative controls do not show any bands
(Figure 2). The CEA mRNA positive rate before HIPEC versus after
HIPEC was 100.0% versus 86.0% (P = .012). The CK20 mRNA
positive rate before HIPEC versus after HIPEC was 100.0% versus
96.0% (P = .495).
Result of Real-Time Quantitative RT-PCR
Relative quantity analysis of real-time quantitative RT-PCR shows
no significant decrease of the relative expression of CEA mRNA and
CK20 mRNA after HIPEC. The relative expressions of CEA mRNA
and CK20 mRNA before HIPEC versus after HIPEC were 4.08 ±
1.34 versus 3.22 ± 0.62 (P = .573) and 0.47 ± 0.09 versus 0.46 ± 0.06
(P = .937), respectively (Figure 3). However, after HIPEC, 18
(36.0%) patients had a decline in CEA mRNA (P = .000) and 17
(34.0%) patients had a decline in CK20 mRNA (P = .000), including
13 (26.0%) patients who had declines in both CEA mRNA and
CK20 mRNA.
Figure 1. Conventional cytology results: positive IFCCs (A) and cytolysis after HIPEC (B) (Wright’s stain, 1000×, scale bar = 10 μm).
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The serum concentrations of CEA, CA125, and CA19-9 before
HIPEC versus after HIPEC were 211.00 ± 156.90 ng/ml versus
41.99 ± 23.67 ng/ml (P = .213), 162.6 ± 46.17 U/ml versus 61.08 ±
10.20 U/ml (P = .015), and 164.00 ± 64.83 U/ml versus 77.53 ±
19.20 U/ml (P = .128), respectively (Figure 4, A–C). Moreover, the
positive rates of serum CEA, CA125, and CA199 before HIPEC
versus after HIPEC were 52.0% versus 28.0% (P = .014), 52.0%
versus 44.0% (P = .423), 40.0% versus 28.0% (P = .205), respectively
(Figure 4D).
Discussion
With the progression of gastrointestinal and gynecological tumors,
cancer cells exfoliate from the serosal surface and scatter into the
peritoneal cavity as IFCCs, which are a major cause of peritoneal
recurrence [14]. Also, division of blood vessels and resection of lymph
nodes during the surgery could make cancer cells spill into peritoneal
cavity to form IFCCs [15]. There are two different processes that
IFCCs could cause PC: the IFCCs attach to peritoneal mesothelial
cells, invade into submesothelial tissue, and form metastatic tumors
with angiogenesis. Or the IFCCs invade into submesothelial
lymphatic space through the milky spots on the peritoneal surface
and form metastatic tumors [16].
Patients with IFCCs have a much higher risk for developing
peritoneal recurrence than those without IFCCs and have a worse
prognosis [17,18]. A number of large-scale clinical trials confirmed
IFCCs as one of themost important prognostic factors. Bando et al. [19]Figure 2. Agarose gel (1.5%) electrophoresis of the RT-PCR product o
to 600 bp (top); lanes 3 to 17 are the patients’ samples; lane 2 is thereported that in 1297 gastric cancer patients, those with IFCCs had a
5-year survival rate of 2%, and of 30 patients who developed PC, 23
were IFCCpositive. Kano et al. [20] reported that in 1039 gastric cancer
patients, the IFCC-positive patients had a 5-year survival rate of 15%,
and the median overall survival was 11 months. Lee et al. [21] reported
172 IFCC-positive gastric cancer patients, of which 76 patients
developed PC. Nashikawa et al. [22] reported that in 410 colorectal
cancer patients, the IFCC-positive patients had a 5-year survival of
20.6% and had 10 times higher risk for developing PC than
IFCC-negative patients. Zuna et al. [23] reported that in 90
IFCC-positive ovarian cancer patients, the median overall survival was
20 months and the 5-year survival rate was 9.2%.
So far, the conventional peritoneal lavage cytology, which has a
high specificity and a low sensitivity [24], is the most reliable
indicator for peritoneal recurrence and the gold standard for detecting
IFCCs [25]. New methods like immunohistochemical [26] and flow
cytometry [27] method using the monoclonal antibodies to detect
tumor-related antigens could partly improve the sensitivity and
specificity over routine cytology. In the 1990s, the extremely high
sensitivity of RT-PCR technique made it possible to diagnose
micrometastasis on the cancer tissue–specific mRNA expression in
peripheral vein [28], bone marrow [13], and lymph nodes [29]. In
1997, Nakanishi et al. [30] first reported the successful use of
RT-PCR for detecting CEA mRNA of the IFCCs in peritoneal lavage
fluid. Kodera et al. [24] reported that using RT-PCR to detect CEA
mRNA of peritoneal lavage fluid could effectively predict the
prognosis of gastric cancer patients. Recently, more and moref CEA (A) and CK20 (B). Lane 1 is a DNAmaker from 100 bp (bottom)
positive control; lane 18 is the negative control.
Figure 3. Relative expressions of CEA mRNA (A) and CK20 mRNA (B) before HIPEC and after HIPEC acquired by real-time quantitative
RT-PCR. Horizontal lines represent mean ± standard error. Before and after mean before HIPEC and after HIPEC.
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because of its higher sensitivity than conventional cytology.
Moreover, the use of multiple biomarkers like CEA, CK20 [31],
CK19 [32], and MMP [33] for RT-PCR assay could greatly improve
both the sensitivity and the specificity of detecting IFCCs and make it
a reliable way for clinical use.
There was still no standard treatment for IFCC-positive patients.
Conventional radical surgery, which ignores the IFCCs, only focuses
on the organ resection and lymph node dissection. Moreover, even
strictly following the principle of tumor-free technique during the
surgery, some patients who were IFCC negative at laparotomy became
IFCC positive after surgery [34]. So now, simple gastrectomy without
additional lymphadenectomy was still accepted as the optimal strategy
for the treatment. Ito et al. [35] reported that a new oral fluorinated
pyrimidine agent (S-1) may delay cancer relapse for gastric cancer
patients with free cancer cells detected by real-time RT-PCR but not
always eradicate micrometastases. Kuramoto et al. [36] reported thatFigure 4. Serum CEA (A), CA125 (B), and CA19-9 (C) concentratio
with positive serum CEA, CA125, and CA19-9 (D). The definitions of p
and ≥ 37 U/ml, respectively. Horizontal lines represent mean ± stanextensive intraoperative peritoneal lavage followed by intraperitoneal
chemotherapy could significantly improve the 5-year survival span of
gastric cancer patients with IFCCs and recommended this treatment
as a standard prophylactic strategy for peritoneal dissemination.
HIPEC was also reported to be effective for the prevention of
recurrence in patients with IFCCs [37] and be an independent
prognostic factor for improving the overall survival of patients with PC
that originated from gastric cancer [8], colorectal cancer [38], and
ovarian cancer [39].
In this study, conventional peritoneal lavage cytology, conven-
tional RT-PCR, and real-time quantitative RT-PCR methods were
used for detecting IFCCs. Before HIPEC, the IFCC, CEA mRNA,
and CK20 mRNA positive rates achieved by these methods were all
100%, far more than the other studies had reported [2,26,30,33],
because the patients included in this study were all with visible
peritoneal recurrence (median PCI = 22, range = 2-39). However,
IFCC, CEA mRNA and CK20 mRNA positive rate became 22.0%ns before HIPEC and after HIPEC, and the number of patients
ositive serum CEA, CA125, and CA19-9 were ≥5 ng/ml, ≥35 U/ml,
dard error. Before and after means before HIPEC and after HIPEC.
Translational Oncology Vol. 9, No. 1, 2016 Assessment of Hyperthermic Intraperitoneal Chemotherapy Ji et al. 23(P = .000), 86.0% (P = .012), and 96.0% (P = .495) after HIPEC,
respectively. Even though HIPEC could not realize significant decline
of CEA mRNA and CK20 mRNA positive rates, the relative quantity
analysis shows that the relative expression of CEA mRNA decreased
in 18 (36.0%) patients (P = .000) and the relative expression of CK20
mRNA decreased in 17 (34.0%) (P = .000). Moreover, the positive
rate of serum CEA also significantly decreased from 52.0% to 28.0%
after HIPEC (P = .014).
In China, most of the patients with malignancy were diagnosed at
an advanced stage; traditional radical surgery–based therapy cannot
eradicate the IFCCs, which are the major cause for the high peritoneal
recurrence rate and the poor prognosis. HIPEC combines the
chemotherapeutic effect and the hyperthermic effect and can
eradicate IFCCs effectively. Also, extensive peritoneal lavage of the
heat fluid with chemotherapy drugs can reduce IFCCs. Our results
suggest that HIPEC could achieve partial cytological cure for PC.
More studies and long follow-up are needed to verify the impact of
this approach on patient outcomes.
Conclusion
HIPEC could effectively eradicate IFCCs and partially achieve
cytological cure for PC.
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